Posted Aug. 25, 2017 at 8:35 a.m.

Premium Lock Durham startup lands rights to Duke antibody for cancer immunotherapy

Published: 2017-08-25 08:35:00
Updated: 2017-08-25 08:35:00

Grid Therapeutics Grid Therapeutics Image 1 of 2 · Next Image…

Durham-based Grid Therapeutics, an oncology-focused biotechnology company, has signed an exclusive license agreement with Duke University to develop the first human-derived antibody as a targeted immunotherapy for cancer....

Read More
Read More

WRAL TechWire any time: Twitter, Facebook

Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Latest for Insiders